Top Raleigh, NC Health Tech Companies With Best Stability & Growth (70)

Strong Revenue Growth: Galleri and total revenue have risen consistently, with full-year 2025 up 17% and U.S. Galleri up 26%, followed by Q1–Q2 2026 total revenue gains of 28% and 26% alongside 50% and 35% volume growth. This cadence, including Q4 2025 Galleri revenue up 31%, indicates sustained commercial momentum after the June 2024 spin‑off.

Strategic Partnerships: Channel and platform integrations such as Epic EHR and Quest Diagnostics, plus collaborations like Samsung for Asian commercialization, are expanding access and streamlining ordering. Additional distribution wins (e.g., Priority Health employer plans and digital health channels) reinforce multi‑channel penetration for Galleri.

Investor Backing & Capital Strength: The company reports a substantial cash balance (~$861.6M as of Q2 2026) and closed a $110M equity financing with Samsung, bolstering financial flexibility. Public listing post‑spin‑off further enhances capital‑markets access to fund trials and commercialization.

Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.

Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.

Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Investor Backing & Capital Strength: Recent $300M financing in March 2026, conversion to a C‑corp, and Alphabet remaining a significant minority investor indicate strong capital access to scale its AI‑native precision health platform. Earlier large rounds and ongoing backing provide resources for expansion while pursuing independence.

Product Line Growth: The company has expanded offerings with the AI‑native Pre platform (including opening Exchange and Workbench self‑serve/free tiers), the Verily Me app, and the Lightpath Metabolic program positioned for broad availability in 2026. These launches and migrations from Onduo signal a cohesive product strategy aimed at broader adoption.

Strategic Partnerships: Partnerships with NVIDIA, Samsung, UCHealth/CU Anschutz, and NIH “All of Us” via Vanderbilt, plus CMS ACCESS model participation, point to growing ecosystem traction. These collaborations expand research and care use cases and distribution channels.

Strong Market Position & Advantage: Aledade is positioned as a category leader in value-based care enablement for independent primary care, supported by its large national network and repeated references to outsized influence in Medicare ACO participation and savings outcomes.

Investor Backing & Capital Strength: The company is described as having substantial funding and financing capacity, including major equity rounds and a large senior secured credit facility intended to support scaling and working-capital needs.

Market Expansion: The organization is described as expanding rapidly in geographic footprint and partner counts, with continued additions of new primary care organizations across dozens of states and growth in covered patient lives.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across recent quarters and the latest fiscal year, with momentum reflected in higher quarterly results and a raised full‑year outlook. Near‑term guidance also points to continued expansion through the remainder of the year.

Profitability: Profitability has expanded alongside growth, with operating income and earnings increasing meaningfully in the latest quarter. A subscription‑heavy mix and higher full‑year operating income guidance support margin durability.

Strong Market Position & Advantage: Position in life‑sciences CRM remains dominant, with a very large share of biopharma seats cited by management and many top‑20 pharmas live on next‑gen Vault CRM. Broad adoption across Development and Quality Clouds and continued big‑pharma commitments reinforce competitive advantage.

Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.

Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.

Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.

Strong Market Position & Advantage: Dominant leadership is reinforced by being a pioneer in robotic-assisted surgery and maintaining a large, entrenched installed base that drives broad adoption. Competitive moats are further supported by surgeon training and ecosystem stickiness tied to hospital investments and workflow standardization.

Strong Revenue Growth: Revenue is described as growing strongly year over year, alongside sustained multi-year growth and forward projections that indicate continued expansion. Procedure volumes are also rising at a double-digit pace, supporting ongoing demand for the core platform.

Diversified Revenue Streams: A large share of revenue is characterized as recurring, driven by instruments, accessories, services, and usage tied to procedure volume rather than one-time system sales. This mix supports a steadier business profile as the installed base expands.

Strong Market Position & Advantage: The company is repeatedly characterized as the nation’s leading or premier platform for integrating health and social care, powering the largest outcomes-driven network with broad statewide programs and measurable impact. Recognition such as inclusion on TIME’s 2025 World’s Top HealthTech Companies and large-scale deployments reinforce a durable competitive position.

Strategic Partnerships: Relationships span major health systems and insurers and statewide government initiatives, alongside backing from prominent investors. State Medicaid initiatives and Social Care Networks selecting the platform indicate embedded ties across payers, providers, and community organizations.

Innovation-Driven Growth: Acquisitions like Carrot Health and NowPow expanded analytics and referral capabilities, while product enhancements added predictive analytics, closed-loop referrals, and integrated eligibility and payments. Ongoing platform updates and AI-driven features are intended to improve ROI and accelerate adoption.

Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.

Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.

Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.